Wells Fargo Maintains Overweight on Ascendis Pharma, Lowers Price Target to $134
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Ascendis Pharma (NASDAQ:ASND) but lowered the price target from $139 to $134.
September 06, 2023 | 5:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ascendis Pharma's price target has been lowered by Wells Fargo from $139 to $134, though the Overweight rating is maintained.
The news is directly about Ascendis Pharma and is likely to influence investor sentiment. The lowering of the price target might be seen as a negative signal, but the maintenance of the Overweight rating indicates that the analyst still sees the stock as a good investment. The net impact on the stock price in the short term is uncertain, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100